Organ damage proteomic signature identifies patients with MASLD at-risk of systemic complications

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background & objectives

Metabolic steatotic liver disease (MASLD), which affects more than 30% of the world’s population, is associated with multisystemic comorbidities. We combined multidimensional OMICs approaches to explore the feasibility of using high-throughput targeted circulating proteomics to track systemic organ damage and to infer its underlying mechanisms at the molecular level.

Desing

We tested a 92-plex panel of prioritised proteins with pathophysiological relevance to organ damage in serum samples of patients with in-depth phenotyping. We included proteomics data from 60,042 people in the discovery and validation stages. The identified protein was validated across diverse study designs and cross-proteomic platforms. Deconvolution strategies were used to investigate whether the affected liver is involved in expressing biomarkers of organ damage. To assess the cell type-specific transcriptional changes of the selected target we used liver organoid data.

Results

The implicated proteins, including ADGRG1 (GPR56), are deregulated in patients with MASLD at-risk of progressive disease and significant fibrosis. ADGRG1 liver expression profile mirrors the circulation pattern. ADGRG1 levels were associated with increased risk of end-stage liver disease and a modest but clinically significant risk of death, chronic obstructive pulmonary disease, and ischaemic heart disease over 16 years of follow-up. Mechanistic insight shows that ADGRG1 shifts its transcriptional profile from low expression to upregulation in liver cells of the fibrotic niche in response to injury.

Conclusions

Our study provides a framework of potential mechanisms associated with systemic organ injury that facilitates holistic management by stratifying patients with MASLD into subclasses at-risk of extrahepatic manifestations.

Article activity feed